Derisk early and accelerate antibody development with mass photometry -column-free aggregation assessment and in solution binding mechanisms

Purity, aggregation state, and target binding are critical quality requirements that need to be monitored throughout the antibody development cycle as they impact product efficacy and safety. Yet, traditional chromatographic technologies for their assessment were primarily established for monoclonal antibody (mAb) IgG formats and can be difficult to optimize for larger IgM complexes or newer bispecific antibody (bsAb) formats.

 

Mass photometry (MP) is a modality agnostic technology that can assess aggregation and target binding in different antibody formats after a simple one step optimization. MP directly measures the mass of individual particles in solution with native buffers using only nanograms of sample in minutes.

 

In the first part of this webinar, we will compare the performance of MP and SEC-HPLC in the determination of antibody purity and aggregation in different antibody formats. In cases where meaningful data could be obtained from SEC-HPLC, MP measurements agreed with the SEC-HPLC data and being a single particle measurement could provide superior resolution on oligomeric states. In other cases where meaningful data could not be obtained from SEC-HPLC, MP was able to provide a fast reliable assessment of antibody purity/aggregation.

 

In the second part, we will delve into antibody-antigen binding mechanisms of mAbs and bsAbs, and how MP can be used to measure binding stoichiometry and binding affinities associated with the different stoichiometries.

 

 

 

Mass photometry enhances antibody development workflows with insights from: